Metabolic dysfunction-associated fatty liver disease (MAFLD)
Conditions
Interventions
Control Group:Basic treatment + routine Western medicine (Silymarin capsules / Polyene phosphatidylcholine capsules)
Treatment group:Conventional treatment + Ganoderma lucidum Xiaoyuxuetang decoction
Sponsors
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Meets the criteria for liver fibrosis according to MASLD; 2. Meets the diagnostic criteria for qi deficiency and blood stasis syndrome; 3. Accepts HXD or conventional liver-protecting treatment; 4. Has complete follow-up data for at least 24 weeks.
Exclusion criteria
Exclusion criteria: 1. With other liver diseases or malignant tumors; 2. Decompensated cirrhosis, hepatocellular carcinoma; 3. Incomplete data or concurrent use of other traditional Chinese medicines; 4. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hepatic steatosis;liver stiffness; | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver Function;blood lipids;Body Mass Index;TCM Syndrome Score; | — |
Countries
China
Contacts
Public ContactCheng Yang
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Outcome results
None listed